Faculty profile

Dominique Farge

ResearcherMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.

Dominique Farge

Researcher

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
29 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,132

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Mesenchymal Stem Cells Randomized Clinical Trial Systemic Sclerosis

Latest papers

Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group.
Clinical and experimental rheumatology · 2026 · senior author
Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).
Bone marrow transplantation · 2026
Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.
Cytotherapy · 2026 · senior author

All 59 publications

Latest funding

Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis
CIHR · 2019 · Principal investigator
$421,515

All 1 grants and awards

59 publications.

Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group.

Biard L, Pugnet G, Cacciatore C, Prata PH, Crichi B, Urbain F, Munia I, Lansiaux P, Le Maignan C, Farge D

Clinical and experimental rheumatology2026Senior author

DOI: 10.55563/clinexprheumatol/8o94lv PMID: 41537538

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Kirgizov K, Greco R, Badoglio M, Labopin M, Saccardi R, Rovira M, Farge D, Roeven MWH, Moore J, Mehra V, Onida F, Polushin A, Finke J, Alexander T, Burman J, Del Papa N, Greenfield DM, Kazmi M, Rovo A, Salooja N, Schoemans H, Sharrack B, Nozzoli C, Tichelli A, Bader P, Corbacioglu S, Peric Z, Roldan E, Basak GW, Snowden JA

Bone marrow transplantation2026

DOI: 10.1038/s41409-026-02983-1 PMID: 42509429

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.

Nivet M, Munia I, Crichi B, Alsuliman T, Blasi RD, Sabbah M, Le Tallec E, Khelifa SH, Beuvon C, Charles C, Jachiet M, Terriou L, Pugnet G, Maria A, Dhote R, Prata PH, Marjanovic Z, Koh M, Thieblemont C, Farge D, Maladies Auto Immunes et Thérapie Cellulaire Group-Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Cytotherapy2026Senior author

DOI: 10.1016/j.jcyt.2026.102057 PMID: 41775117

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Blanc KL, Dazzi F, English K, Farge D, Galipeau J, Horwitz EM, Kadri N, Krampera M, Lalu MM, Nolta J, Patel NM, Shi Y, Weiss DJ, Viswanathan S

Cytotherapy2025

DOI: 10.1016/j.jcyt.2025.01.005 PMID: 39864015

Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study.

Farge D, Biard L, Weil B, Girault V, Lansiaux P, Munia I, Loisel S, Charles C, Saout J, Resche-Rigon M, Korganow AS, Beuvon C, Pugnet G, Cacciatore C, Abisror N, Taupin JL, Cras A, Lowdell MW, Tarte K

The Lancet. Rheumatology2025First author

DOI: 10.1016/s2665-9913(24)00298-4 PMID: 39706212

Successful autologous haematopoietic stem cell transplantation in a refractory anti-myelin-associated glycoprotein antibody neuropathy.

Urbain F, Labeyrie C, Castilla-Llorente C, Noel N, Farge D, Echaniz-Laguna A

British journal of haematology2025

DOI: 10.1111/bjh.19969 PMID: 40052451

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.

Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, Snowden JA, Alexander T, Amato MP, Bø L, Boffa G, Ciccarelli O, Cohen JA, Derfuss T, Farge D, Freedman MS, Gaughan M, Heesen C, Kazmi M, Kirzigov K, Ljungman P, Mancardi G, Martin R, Mehra V, Moiola L, Saccardi R, Tintoré M, Stankoff B, Sharrack B, Attendees of the ECTRIMS Focused Workshop on HSCT

Nature reviews. Neurology2025

DOI: 10.1038/s41582-024-01050-x PMID: 39814869

[Prerequisite and organisation of health-care pathways for Cell and Gene therapies, using Mesenchymal Stromal Cells (MSC) or Chimeric Antigen Receptor (CAR) T cells, in patients with autoimmune systemic diseases].

Castilla-Llorente C, Bonnin A, Lansiaux P, Tudesq JJ, Beuvon C, Fabreguettes JR, Pers YM, Pugnet G, Maria ATJ, Puyade M, Urbain F, Terriou L, Poindron V, Jachiet M, Cacciatore C, Lescoat A, Prata PH, Munia I, Madelaine I, Thieblemont C, Tarte K, Yakoub-Agha I, Magro L, Farge D, Marjanovic Z

Bulletin du cancer2025

DOI: 10.1016/j.bulcan.2024.06.008 PMID: 39242251

Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Alexander T, Roldan E, Del Papa N, Farge D, Henes J, Marjanovic Z, Puyade M, Snowden JA, Spierings J, de Vries-Bouwstra JK, Onida F, Ruggeri A, Sánchez-Ortega I, Burt R, Cervera R, Doria A, Moore J, Oliveira MC, Pugnet G, Rimar D, Schmalzing M, Yakoub-Agha I, Greco R

Bone marrow transplantation2025

DOI: 10.1038/s41409-025-02695-y PMID: 40830237

Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases.

Davies LC, Biard L, García-Olmo D, Gilkeson G, Gnecchi M, Kurtzberg J, Kogler G, Blanc KL, Lowdell MW, Pers YM, Sun LY, Tarte K, Uccelli A, Sanchez-Guijo F, Farge D, ISCT Educational Course Working Group on the Use of Mesenchymal Stromal Cells for Autoimmune Diseases (Paris 2024)

Cytotherapy2025Senior author

DOI: 10.1016/j.jcyt.2025.06.005 PMID: 40828119

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2019

Subject: Prospective PhD student: Mesenchymal Stem Cells Dear Professor Farge, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis" (2019), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Dominique Farge

Research

Latest papers

Latest funding

Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group.

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study.

Successful autologous haematopoietic stem cell transplantation in a refractory anti-myelin-associated glycoprotein antibody neuropathy.

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.

[Prerequisite and organisation of health-care pathways for Cell and Gene therapies, using Mesenchymal Stromal Cells (MSC) or Chimeric Antigen Receptor (CAR) T cells, in patients with autoimmune systemic diseases].

Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases.

Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis

Frequent collaborators

James Demetrios Douketis

Ines Colmegna

Marie Hudson

David Langlais

Nancy Maltez

Sowmya Viswanathan

Murray Baron

Janusz Rak

Russell Steele